Trial Profile
A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms SIMPLIFY
- Sponsors Biogen
- 06 Jul 2015 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016, according to ClinicalTrials.gov record.
- 06 Jul 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016, according to ClinicalTrials.gov record.
- 06 Jul 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.